FDA Drug Safety Communication: FDA to Evaluate Potential Risk of Neural Tube Birth Defects with HIV Medicine Dolutegravir

Date

Source FDA Drug Safety Communication: FDA to Evaluate Potential Risk of Neural Tube Birth Defects with HIV Medicine Dolutegravir